In this article we will list 10 underperforming stocks targeted by short sellers.
Short-sellers have invited the wrath of millions on the internet, causing one of the biggest short squeezes in the history of financial markets. Year to date, GameStop short sellers alone have lost close to $5 billion, according to a report. The army of retail investors, day traders and “YOLO investors” are now paying a lot of attention to other stocks that are shorted by major hedge funds. Despite the inherent risks and misunderstandings linked to it, short-selling is a proper investment strategy that has its rationale, thesis and roots. Unlike the common opinion, short-sellers are not looking to make profits by ruthlessly targeting random companies without any reason. Short-selling involves speculating on the decline of a stock based on its valuation concerns, internal fraud, financial vulnerabilities and other problems. Usually, hedge funds and institutional investors engage in short-selling strategies for both speculation and hedging. They short positions in certain stocks or sectors to hedge their long positions in other stocks (see 25 Biggest Activist Short Sellers).
Full Of Risks
However, short-selling strategy is risky, especially when used in a bull market. Looking at the current situation of the Wall Street short-sellers, legendary economist John Maynard Keynes’ famous adage comes to mind: “The market can stay irrational longer than you can stay solvent.“
The market might be irrational to the short-sellers, but it sure is driving them to the verge of unacceptable losses. Why is short-selling a risky approach? The stock market in the long run almost always tends to go up, while short-selling is a bearish investment strategy that is betting for the decline of a stock or sector. Short-selling is often best for sophisticated investors who know the ins and outs of the companies they are shorting. Short-selling is highly risky for individual investors because there’s no limit on losses you could incur. For example, when a stock is shorted, and investors are already buying that stock, its price goes up. Short-sellers start buying that stock to cover their position and minimize losses, resulting in a “short squeeze.” If you buy a stock, you can only lose 100% of your money (in case the stock goes to $0). But if you short a stock, there’s not limit to potential losses as there is no ceiling for a stock’s price. To borrow the phrase of Reddit investors, it can rise “to the moon.”
Full of Rewards?
And yet short-selling has made hedge funds and expert investors extremely rich and profitable. Last year, Pershing Square’s Bill Ackman made $2 billion in profits just by betting against the market, based on his prescient forecast: “hell is coming.” Last year, short-sellers made close to $50 billion in profits in just 7 days amid the coronavirus-triggered selloff. There were hundreds of short bets that paid off in the year. Click to read the Top 10 Activist Short Calls That Paid Off in the First Half of 2020.
The GameStop episode exacerbated the problem for the hedge fund industry. The industry’s reputation has already been tarnished in the last decade during which its hedged returns couldn’t keep up with the unhedged returns of the market indices. On the other hand, Insider Monkey’s research was able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by more than 88 percentage points since March 2017 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that significantly underperformed the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 13% through November 16. That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to. You can subscribe to our free newsletter on our homepage to receive our stories in your inbox.
Image By peshkov – Adobe Stock
In this article we will take a look at top 10 underperforming stocks targeted by short-sellers. Our list is based on the worst-performing stocks over the last 12 months that have the highest short interest.
10. Baudax Bio Inc (NASDAQ: BXRX)
Short % of Float (Jan 14, 2021): 10.12%
Short % of Shares Outstanding (Jan 14, 2021): 9.75%
Baudax is a Pennsylvania-based pharmaceutical company known for its ANJESO injection, which is used to manage moderate to severe pain. The injection received FDA approval based on data from three Phase III clinical trials.
Baudax stock is down a whopping 84% over the last 12 months. Just 7 hedge funds tracked by Insider Monkey held stakes in the company, as of the end of the third quarter.
Short % of Float (Jan 14, 2021): 15.77%
Short % of Shares Outstanding (Jan 14, 2021): 15.69%
California-based Zogenix develops treatments for rare diseases. Its lead product is Fintepla, a treatment of seizures associated with Dravet syndrome. The company is also known for MT1621, an investigational deoxynucleoside substrate enhancement therapy for the treatment of inherited mitochondrial DNA depletion disorder thymidine kinase 2 deficiency.
Read more: Were Hedge Funds Wrong About Piling Into Zogenix, Inc. (ZGNX)?
ZGNX is down 62% over the last 12 months.
8. Callon Petroleum Company (NYSE: CPE)
Short % of Float (Jan 14, 2021): 25.45%
Short % of Shares Outstanding (Jan 14, 2021): 18.16%
Callon Petroleum is an oil and natural gas company focused on the acquisition, exploration and development of high-quality assets in West and South Texas. In November 2020, Callon posted a Q3 Non-GAAP EPS of $0.64, beating the Wall Street by $0.55. Revenue in the quarter totaled $269.71 million, beating the consensus estimate by $20.86 million.
As of the end of the third quarter, Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital owns 996,611 shares of the company, worth $4.8 million.
Callon shares are down 52% over the last 12 months.
7. Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP)
Short % of Float (Jan 14, 2021): 23.71%
Short % of Shares Outstanding (Jan 14, 2021): 19.33%
Corbus Pharmaceuticals Holdings, Inc. focuses on the treatment of rare, chronic, and serious inflammatory and fibrotic diseases. The company’s primary product and lead candidate is lenabasum, which is a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes. In November 2020, the company missed analysts’ estimates for its Q3 results, posting a 52% year-over-year decline in revenue.
Corbus shares are down 73% in the last 12 months.
6. Sabre Corp (NASDAQ: SABR)
Short % of Float (Jan 14, 2021): 21.38%
Short % of Shares Outstanding (Jan 14, 2021): 19.45%
Sabre is a Texas-based is a distribution systems provider for air bookings in North America. In 2007, the company was acquired by Texas Pacific Group and Silver Lake Partners. Sabre started trading publicly-trading company in 2014. In December 2020, Sabre shared rallied after Morgan Stanley upped the stock rating from Equal-Weight to Overweight, and also increase its price target to $14 from $7. In the same month, Mizuho also upgraded Sabre from Underperform to Neutral, citing the slow travel industry recovery.
But Sabre shares have lost half of their value over the last 12 months. Here is what RF Capital said about SABR in its 2020 Q2 investor letter:
“Sabre Corporation (SABR) – This holding never became a large position in our portfolio. However, SABR was a profitable investment for us. We bought at an average price of $4.52/share and sold at $7.38/share. We sold our shares due to the quick gain and the company’s increasing leverage on the balance sheet. The airline and travel industries continue to be challenged, so we wanted to reduce our overall exposure as well.”
SABR shares currently trade above $11.
5. Akebia Therapeutics Inc (NASDAQ: AKBA)
Short % of Float (Jan 14, 2021): 22.93%
Short % of Shares Outstanding (Jan 14, 2021): 19.94%
Akebia is a Massachusetts-based company that is working to treat kidney disease complications. The company has a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), Vadadustat, for the treatment of anemia due to CKD. Vadadustat has not been approved by the FDA or any other regulatory authority for use outside of Japan.
Akebia shares are down about 59% in the last 12 months. A total of 18 hedge funds in Insider Monkey database held stakes in Akebia as of the end of the third quarter, down from 25 funds a quarter earlier.
4. Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)
Short % of Float (Jan 14, 2021): 20.17%
Short % of Shares Outstanding (Jan 14, 2021): 19.99%
New Jersey-based Cyclacel claims to be developing “mechanism-targeted drugs” to treat cancer, diabetes and HIV. The company was founded in 1996 by David Lane, Merlin Ventures and Cancer Research Campaign Technology with the University of Dundee and the University of Glasgow.
Cyclacel shares are down 46% over the last 12 months. Hal Mintz’s Sabby Capital owns 125,578 shares of the company, worth $458,000.
3. Intercept Pharmaceuticals Inc (NASDAQ: ICPT)
Short % of Float (Jan 14, 2021): 34.23%
Short % of Shares Outstanding (Jan 14, 2021): 21.59%
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) develops novel synthetic bile acid analogs to treat chronic liver diseases like primary biliary cirrhosis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension and bile acid diarrhea. The company’s primary product is 6-ethyl-chenodeoxycholic acid or INT-747, marketed as Ocaliva.
The stock is down more than 62% in the last 12 months. As of the end of the September quarter, 20 hedge funds tracked by Insider Monkey held stakes in the company.
2. Invesco Mortgage Capital Inc (NYSE: IVR)
Short % of Float (Jan 14, 2021): 26.25%
Short % of Shares Outstanding (Jan 14, 2021): 22.33%
Invesco is a Georgia-based REIT that primarily deals in commercial mortgage-backed securities and other mortgage-related assets. The company also invests in residential mortgage-backed securities. Its previous name was Invesco Agency Securities Inc. which was changed in 2008. The stock is down 76% over the last 12 months. In December 2020, the company declared a quarterly dividend of $0.08 per share, a 60% increase from prior dividend of $0.05.
A total of 9 hedge funds out of 816 tracked by Insider Monkey held stakes in Invesco as of the end of the third quarter.
1. Seritage Growth Properties Class A (NYSE: SRG)
Short % of Float (As of Jan. 14): 59.85%
Short % of Shares Outstanding: 23.04%
Seritage Growth shares are down 52% over the last 12 months. The company is a self-administered REIT with 183 wholly-owned properties and 28 JVs, totaling to about 28.5 million square feet of space across 45 states in the U.S. and Puerto Rico. In November 2020, the company appointed Amanda Lombard as chief financial officer, replacing the outgoing CFO Brian Dickman. In December, the company said its CEO Benjamin W. Schall is resigning from his role.
The stock is down 52% over the last 12 months.
Please also see 10 Cheap Stocks Billionaire Lee Cooperman Is Buying and 10 Extreme Dividend Stocks With Huge Upside.
Follow Insider Monkey on Twitter
Suggested Articles:
- 10 Cheap Stocks Billionaire Lee Cooperman Is Buying
- 10 Extreme Dividend Stocks With Huge Upside
- 11 Best Lithium and Battery Stocks To Buy Now
Disclosure: None. 10 Underperforming Stocks Targeted By Short Sellers is originally published at Insider Monkey.
